Close menu

SURE

Sunderland Repository records the research produced by the University of Sunderland including practice-based research and theses.

Emerging evidence of activity of BLU-945 in patients with advanced EGFR-mutant NSCLC utilizing circulating tumor DNA in the phase 1/2 SYMPHONY study

Mdegela, Mselenge (2022) Emerging evidence of activity of BLU-945 in patients with advanced EGFR-mutant NSCLC utilizing circulating tumor DNA in the phase 1/2 SYMPHONY study. In: American Association for Cancer Research (AACR), 08-13th Apr 2022, New Orleans.

Item Type: Conference or Workshop Item (Poster)

Abstract

BLU-945, a highly potent and selective oral EGFR inhibitor, was generally well tolerated at clinically active doses in heavily pre-treated patients with EGFRm NSCLC, with few AEs characteristic of wildtype EGFR toxicity observed at doses up to 400 mg QD. Despite presence of EGFR mutations conferring resistance to osimertinib, treatment with BLU-945 resulted in rapid dose-dependent reduction in ctDNA, consistent with preclinical data. Increasing BLU-945 doses were associated with increasing antitumor activity, with tumor shrinkage noted at doses of 200 mg QD and above, including an unconfirmed partial response at 400 mg QD. The clonal evolution and resulting mutational complexity of EGFR driven NSCLC tumor cells demonstrates the need for precision medicine combinations to improve clinical outcomes. Initial safety and clinical activity results from the phase 1 SYMPHONY trial support expanded clinical development of BLU-945 in combination with osimertinib and other complementary agents. Dose escalation continues to determine the MTD and RP2D of BLU-945 as a monotherapy and in combination with Osimertinib.

[img]
Preview
PDF (A poster presented at the AACR conference in 2022 in Los Angels.)
Blueprint-Medicines-AACR-2022-BLU-945-SYMPHONY-Trial-EGFR-Mutant-NSCLC-Poster.pdf.pdf - Published Version

Download (2MB) | Preview

More Information

Related URLs:
Depositing User: Mselenge Mdegela

Identifiers

Item ID: 17240
URI: http://sure.sunderland.ac.uk/id/eprint/17240
Official URL: https://www.blueprintmedicines.com/wp-content/uplo...

Users with ORCIDS

ORCID for Mselenge Mdegela: ORCID iD orcid.org/0000-0002-0374-6583

Catalogue record

Date Deposited: 24 Jan 2024 09:46
Last Modified: 24 Jan 2024 10:00

Contributors

Author: Mselenge Mdegela ORCID iD
Author: Mselenge Mdegela

University Divisions

Faculty of Health Sciences and Wellbeing > School of Psychology

Subjects

Sciences > Biomedical Sciences
Sciences

Actions (login required)

View Item (Repository Staff Only) View Item (Repository Staff Only)